Interleukin-1β in neuroinflammation associated to Alzheimer disease by López Zambrana, Patricia & Universitat Autònoma de Barcelona. Facultat de Biociències
Interleukin-1β in Neuroinflammation associated to Alzheimer 
disease
López Zambrana, Patricia. Grau en Biologia UAB
Aims
• The main objective of this study consists in to obtain an overview of the neuroinflammation
involved in Alzheimer disease.
• Considering several perspectives rely on a wide range of experimental models, to discuss
whether a neuroinflammatory mediator which takes part on pro-inflammatory mechanisms,
acts as a one of principal responsible in pathogenesis associated to Alzheimer disease.
• Get to know the processing and regulation of interleukin-1β throughout NLRP3
inflammasome assembly. Otherwise, treatments for Alzheimer disease by inflammasome
inhibition are proposed.
Methods. Literature search of papers in databases like Pubmed restricting to Alzheimer
disease, neuroinflammation, interleukin 1β and NLRP3. In addition, information found in
scientific journals that contains the topic treated. Finally, selection of the most relevant
papers and its treatment to write the discussion.
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Interleukin- 1β, NLRP3 inflammasome, Alzheimer disease: 
- Signal 1: 
Inmature Pro-IL-1β is transcribed throughout NF-kB factor.
- Signal 2:
There are some factors which active the NLRP3 inflammasome. 
assembly such as ROS production or K+ efflux.
NLRP3 oligomeration serve as a platform to caspase -1.
Caspase-1 lets the maturation  of pro-IL-1β into IL-1β. 
- IL-1β is released by microglial cells due to the interaction with seniles 
plaques. The continuos production of citoquines triggers a high levels of 
neuroinflammation that contributes to patology. 
• Neuroinflammation is necessary to maintain homeostasis by the protection against
external and intrinsic factors that could cause damage. On the other hand, under high
activation or extended time, it becomes injury.
• It is well known that, immune responses are mechanisms tightly correlated. So, it is
difficult to describe all process involved in neuroinflammation. Then, how the response
in patients with Alzheimer is carry out has been wide studied and is still in developing.
• Interlequin-1β seems to be the key mediator in Alzheimer disease. Some evidences
show raised levels of Interleuquin-1 β in conditions of pathology. The interaction with
Aβ and microglia increase this citoquines and results in neuroinflammation.
• The assumption that NLRP3 and caspase-1 should be coexpress for IL-1 β production is
shown in some experiments. These mediators act indirectly in neuroinflammation. It is
the reason for new treatments with its inhibition have been tested.
• The huge variability in organisms and between them cause difficulties for pathogeny
investigators. Moreover, found a new treatment is not easy because of elevated
interconexion in the inmune responses. Some pro-inflammatory inhibitors require
more studies to be used as a treatment to in the future.
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